Dr. John Carlo Trials of Cabotegravir so successful, GSK ends trials early Tammye Nash | Managing Editor nash@dallasvoice.com HIV Advocates this week applauded news of a new drug for use in pre-exposure prophylaxis regimens that has proven so successful in trials that the trials were ended early. ViiV Healthcare — majority owned by GlaxoSmithKline with … Continue reading HIV advocates hail new long-lasting PrEP option